ACHV

ANALYST NOTE: ACHV (Achieve Life Sciences, Inc.) Date: 2026-06-13

(1) Structural Readiness As of the close on 2026-06-13, ACHV presents a confirmed coil setup. The structural readiness is defined by a conservative entry level of $6.53. The current price is $6.40, representing an extension of -2.0% relative to the conservative entry. The setup is currently in a "context-only" state where the breakout has fired, but the price is trading slightly below the initial conservative entry threshold. The ATR at breakout was 6.5% (classified as *very_high*), indicating significant structural volatility at the setup formation. The current ATR is 7.1% (also *very_high*), reflecting elevated intraday volatility. While the price is currently below the conservative entry, the presence of a confirmed coil with high ATR suggests a volatile, high-conviction environment where the setup structure remains intact. There is no active "forming" phase; the setup is confirmed, though the price action is currently testing the entry zone.

(2) The Thesis Layer As of this date, ACHV is classified as a TACTICAL, setup-led name. There is no named secular thesis attached to this specific setup in the current context. The investment case must be judged strictly on the quality of the technical setup (the confirmed coil) and the immediate business fundamentals regarding the regulatory status of cytisinicline. No macro or secular themes are being applied to weight this conviction; the focus remains on the binary nature of the upcoming resubmission and the structural volatility of the name.

(3) The Business Achieve Life Sciences is a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of cytisinicline, a novel treatment for nicotine dependence.

• Product & Indication: Cytisinicline is the company's sole product candidate, targeting smoking cessation and vaping cessation. Management notes that while nearly 50 million U.S. adults use nicotine (25 million smokers, 18 million vapers), there has been no new FDA-approved smoking cessation therapy in over two decades, and no approved therapy for vaping cessation (Evidence E4, E5, E6).
• Clinical Data: In trials involving patients with prior varenicline and bupropion use, 12 weeks of cytisinicline achieved continuous abstinence rates of 32.4% versus 6% on placebo, with an odds ratio of 7.5 (Evidence E8).
• Regulatory Status & Manufacturing: The company submitted its NDA in June 2025. On June 22, 2026, the FDA issued a Complete Response Letter (CRL). The CRL cited deficiencies related to a third-party manufacturing facility (Adare Pharma Solutions was previously mentioned, but the CRL noted issues with a *separate* third-party manufacturer included in the original submission) and labeling, but no efficacy or clinical safety deficiencies were identified (Evidence E3, E25, E27).
• Management Expectations: Management expects to resubmit the NDA in the fourth quarter of 2026, naming Adare Pharma Solutions as the new primary manufacturing partner to mitigate supply chain risk (Evidence E1, E18). The stated expectation is for a commercial launch in the first half of 2027 (Evidence E2).
• Financial Position: The company recently completed a private placement raising $180 million in upfront capital, plus up to $174 million in milestone-based warrants exercisable upon FDA approval (Evidence E7, E11). For the three months ended March 31, 2026, the company reported a net loss of $10.2 million and net cash used in operating activities of $6.9 million (Evidence E16). A New Convertible Term Loan matures on June 1, 2028 (Evidence E10).

(4) The Archetype and Conviction ACHV fits the Growth Leader archetype, specifically as a late-stage biopharmaceutical company with a clear path to commercialization pending regulatory resolution.

• Conviction Drivers: The conviction is driven by the high-quality clinical data (32.4% abstinence rate), the massive addressable market (25 million smokers, 17 million vapers), and the recent infusion of capital ($180M) which de-risks the immediate runway. The structural quality is elevated, evidenced by the very_high ATR (6.5% at breakout, 7.1% current), which aligns with the historical profile of high-impact biotech catalysts.
• Setup Quality: The confirmed coil setup suggests institutional accumulation or a re-pricing of the CRL event. The high volatility (ATR) indicates that the market is actively digesting the regulatory news, creating a potential for significant price movement once the resubmission path is clarified.
• Rerating Potential: The rerating potential is binary and tied to the Q4 2026 resubmission. If the manufacturing issues are resolved as management expects, the market may re-rate the stock from a "regulatory risk" asset to a "near-commercial" asset.

(5) Invalidating Factors, Strengthening Factors, and Gaps

• What would Strengthen the Case: A clear, positive communication from the FDA regarding the specific manufacturing remediation plan prior to the Q4 resubmission. Confirmation that Adare Pharma Solutions is fully qualified and ready for commercial-scale production.
• What would Invalidate the Case: A second CRL or a delay in the Q4 2026 resubmission timeline. If the FDA indicates that the manufacturing issues are not "fixable" or require a new clinical trial, the thesis would be compromised.
• Gaps in Evidence: The specific details of the "remedial action plan" for the third-party manufacturer are not fully detailed in the provided evidence, only that it is "being addressed." The exact timeline for the Adare partnership to become operational is management's expectation, not a confirmed milestone date. There is no evidence on the specific pricing or reimbursement strategy for cytisinicline, which is critical for the 2027 launch.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Confirmed coil setup with very_high ATR indicating structural volatility; $180M capital raise de-risks near-term runway; CRL explicitly cites only manufacturing/labeling issues, not efficacy or safety. Key risks: FDA may not accept the Q4 2026 resubmission timeline; manufacturing remediation could take longer than expected, delaying launch; binary regulatory outcome creates high volatility. Rating boundary: This is rated Speculative rather than Buy because the CRL has just been received and the resubmission is a future event (Q4 2026) with no guarantee of success; the price is currently below the conservative entry, indicating the market is still pricing in the regulatory risk. It is not a Sell because the clinical data is strong, the capital is secured, and the CRL is fixable per management. Sizing hint: Position size should reflect the binary nature of the upcoming resubmission and the high ATR; use smaller sizing to account for potential volatility spikes around the Q4 announcement. Expected path: Management executes the resubmission in Q4 2026; if accepted, the stock re-rates toward commercial launch expectations in H1 2027. Expected horizon: 6 to 12 months (through Q4 2026 resubmission and potential approval). Failure mode to watch: FDA rejects the resubmission or requests additional clinical data, pushing the timeline beyond H1 2027.